Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
This bill authorizes $10 million per year for fiscal years 2026–2030 to the National Institute of Neurological Disorders and Stroke to conduct or support comprehensive research on unruptured intracranial aneurysms. Funding must supplement, not supplant, other brain aneurysm research and remain available through September 30, 2033.
Debate over whether $10M/year is adequate funding
Relative to its intended legislative type, this bill functions primarily as an authorization of appropriations for research at NINDS and clearly defines the problem and funding amounts.
This bill authorizes $10 million per year for fiscal years 2026–2030 to the National Institute of Neurological Disorders and Stroke to conduct or support comprehensive research on unruptured intracranial aneurysms.
Funding must supplement, not supplant, other brain aneurysm research and remain available through September 30, 2033.
The bill’s findings describe prevalence, mortality, demographic differences, economic costs, and several personal case narratives supporting expanded research.
Narrow, low-controversy authorization with modest fiscal impact increases chances, but enactment depends on future appropriations and legislative scheduling.
Relative to its intended legislative type, this bill functions primarily as an authorization of appropriations for research at NINDS and clearly defines the problem and funding amounts. It provides a basic implementation anchor (agency and funding timeline) but lacks programmatic detail, statutory integration, and any reporting or accountability provisions.
Debate over whether $10M/year is adequate funding
These are examples from the analysis, not a ranked list of the most-affected groups.
Debate over whether $10M/year is adequate funding
Generally strongly supportive because it expands federal research into a life‑threatening condition and highlights demographic disparities.
Likely to welcome emphasis on diversified study populations, while wanting stronger guarantees on equity, open data, and community engagement.
May argue funding level is modest relative to disease burden and look for broader investments.
Likely supportive as a targeted, modest federal investment in health research with bipartisan appeal.
Sees the funding as reasonable and focused, but will seek clear accountability, measurable outcomes, and avoidance of duplication.
Views the 'supplement, not supplant' language positively but may request reporting to Congress.
Cautiously supportive because the appropriation is modest and focused on medical research, which can be noncontroversial.
Concerns center on any expansion of federal spending, potential mission creep, and ensuring this truly supplements existing research.
Likely to insist on fiscal restraint and clear sunset or oversight provisions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, low-controversy authorization with modest fiscal impact increases chances, but enactment depends on future appropriations and legislative scheduling.
The bill has not accumulated any surfaced votes yet.
Debate over whether $10M/year is adequate funding
Narrow, low-controversy authorization with modest fiscal impact increases chances, but enactment depends on future appropriations and legis…
Relative to its intended legislative type, this bill functions primarily as an authorization of appropriations for research at NINDS and clearly defines the problem and funding amounts. It provides a basic implementatio…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.